Recombinant Mouse VEGF R2/Flk-1 Fc Chimera Protein (Catalog # 443-KD)
Measured by its ability to neutralize VEGF R2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 0.05-0.15 µg/mL in the presence of 150 ng/mL Recombinant Mouse VEGF R2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Mouse VEGF164.
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
VEGF R2/KDR/Flk‑1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGF R2/KDR/Flk‑1 Antibody. Recombinant Mouse VEGF R2/KDR/Flk‑1 Fc Chimera (Catalog # 443-KD) inhibits Recombinant Mouse VEGF164 (Catalog # 493-MV) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse VEGF164 (5 ng/mL) activity elicited by Recombinant Mouse VEGF R2/KDR/Flk‑1 Fc Chimera (150 ng/mL) is neutralized (green line) by increasing concentrations of Mouse VEGF R2/KDR/Flk‑1 Monoclonal Antibody (Catalog # MAB4431). The ND50 is typically 0.05-0.15 µg/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF R2/KDR/Flk-1
VEGF R2 (KDR/Flk-1), VEGF R1 (Flt-1) and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis. Mouse VEGF R2 cDNA encodes a 1367 amino acid (aa) precursor protein with a 19 aa signal peptide. Mature VEGF R2 is composed of a 743 aa extracellular domain, a 22 aa transmembrane domain, and a 583 aa cytoplasmic domain. In contrast to VEGF R1 which binds both PlGF and VEGF with high affinity, VEGF R2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGF R2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.
Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA 95:548.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.